Analysts Set Galapagos NV (NASDAQ:GLPG) Price Target at $36.50
by Doug Wharley · The Cerbat GemGalapagos NV (NASDAQ:GLPG – Get Free Report) has been assigned an average rating of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $36.50.
Several equities analysts have issued reports on the stock. Weiss Ratings upgraded shares of Galapagos from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. Royal Bank Of Canada upped their price objective on shares of Galapagos from $32.00 to $33.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 24th. Raymond James Financial restated a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Galapagos from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Finally, UBS Group restated a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th.
Check Out Our Latest Analysis on Galapagos
Galapagos Trading Down 0.6%
Shares of GLPG stock opened at $28.40 on Wednesday. The firm has a fifty day moving average price of $32.28 and a 200 day moving average price of $32.54. The company has a market cap of $1.87 billion, a P/E ratio of -18.09 and a beta of 0.32. Galapagos has a 12 month low of $23.36 and a 12 month high of $37.78.
Galapagos (NASDAQ:GLPG – Get Free Report) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The firm had revenue of $1.06 billion for the quarter. On average, equities analysts forecast that Galapagos will post -1.6 EPS for the current year.
Hedge Funds Weigh In On Galapagos
Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Galapagos by 2.1% in the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after acquiring an additional 643 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Galapagos by 79.4% during the third quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock worth $51,000 after buying an additional 652 shares during the period. Van ECK Associates Corp boosted its stake in shares of Galapagos by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after buying an additional 750 shares during the period. Two Sigma Investments LP grew its holdings in shares of Galapagos by 3.7% during the third quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after buying an additional 800 shares during the last quarter. Finally, State of Wyoming purchased a new position in shares of Galapagos during the second quarter worth about $28,000. Institutional investors and hedge funds own 32.46% of the company’s stock.
Galapagos Company Profile
Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.
The company’s pipeline encompasses multiple programs across various stages of development.